Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone

Status unconfirmed · Phase 1

Conditions studied: Substance-Related Disorders

In brief

The purpose of this study is to determine to what extent CYP2B6, CYP3A4, and MDR1 polymorphisms affect the metabolism of methadone.

Key facts

Study ID

NCT00504413

Run by

University of Washington

People needed

20

Starts

2007-07-01

Expected to finish

2011-01-01

Last updated by the study team

2010-10-13

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy
• Within 25% of ideal body weight

You may not qualify if…

• Pregnant
• A prisoner
• Enemy, non-combatant
• Smoker
• Have a history of liver disease
• Have a history of heart disease
• Have a history of drug abuse
• Currently on prescription medication

Where it is running

• University of Washington General Clinical Research Center — Seattle, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.